Current Good Manufacturing Practices & Good Manufacturing Practices: Pharmaceutical Compliance Guide 2026

As the global CDMO market races toward $342 billion by 2035, Current Good Manufacturing Practices and Good Manufacturing Practices compliance have become the deciding factor separating trusted pharmaceutical manufacturing partners from the rest. This PharmaSource guide explains what cGMP and GMP require, how enforcement is shifting in 2026, and what to look for when vetting a CDMO partner.

Market Overview: GMP Pharmaceutical Manufacturing Demand Is Accelerating

What is Good Manufacturing Practice (GMP) and why does it matter in pharmaceutical manufacturing?

GMP is the regulatory framework that governs how medicines are produced, tested, and released to ensure every batch is safe, effective, and consistent. It matters because non-compliance can trigger recalls, import bans, or facility shutdowns — outcomes that damage patients and companies alike.

According to Global Market Insights (2026), the global pharmaceutical CDMO market reached $173.7 billion in 2025 and is projected to grow from $184.9 billion in 2026 to $342 billion by 2035, a 7.1% compound annual growth rate. A narrower slice of that market contract pharmaceutical manufacturing specifically is estimated at $255.74 billion in 2026, growing to $501.55 billion by 2033 at a 10.1% CAGR, according to Coherent Market Insights (2026). Both trajectories point to the same conclusion: as outsourcing deepens, GMP compliance capability is becoming a primary differentiator between CDMOs, not a baseline assumption.

Three macro trends are shaping this space heading into 2026:

• Enforcement is intensifying, not relaxing. FDA officials have stated publicly that contract manufacturers and testing labs are treated as extensions of the sponsor’s own facility, meaning a CDMO’s compliance failure becomes the sponsor’s regulatory problem, according to IntuitionLabs (2026).
• Data integrity remains the dominant citation driver. Industry analyses consistently find that 60–80% of GMP warning letters include data integrity findings as a contributing factor, according to Zamann Pharma (2026).
• AI governance has entered GMP enforcement. FDA issued its first warning letter citing AI misuse as a GMP breach in April 2026, after a company’s AI agents drafted cGMP specifications and records without human review, according to Certainty Software (2026).

These trends are converging with a broader regulatory modernization push. At the 2026 ISPE European Annual Conference, EMA confirmed active work on revising EU GMP guidance, with particularly heavy industry engagement around Chapter 4 (documentation), Annex 11 (computerized systems), and the newly proposed Annex 22 addressing artificial intelligence in manufacturing and quality operations, according to GMP-Publishing (2026). For CDMOs and sponsors operating across US and EU jurisdictions, this means dual-track compliance planning is becoming necessary rather than optional, since the two regions are tightening AI oversight expectations on parallel but not identical timelines.

Latest GMP News-

Good Manufacturing Practice Overview

Good Manufacturing Practice is the set of regulations, guidelines, and quality systems that ensure pharmaceutical products are consistently manufactured and controlled to defined quality standards, from raw material intake through finished product release.

GMP operates across five interconnected pillars, often described as the 5 P’s: People, who require documented training and competency verification; Products, which undergo testing and stability validation across their lifecycle; Processes, standardized through validated Standard Operating Procedures; Procedures, which govern deviation handling and corrective action; and Premises, where facility and equipment qualification (IQ/OQ/PQ) confirms controlled operating conditions.

In practice, GMP functions less like a single rulebook and more like a coordinated system: procedures define how work should be done, personnel are trained and assessed against those procedures, equipment and facilities are qualified to support them, and documentation captures evidence that the system actually worked as intended. When any one of these elements breaks down — an untrained operator, an unqualified piece of equipment, an incomplete batch record — the entire chain of evidence supporting product quality is compromised, which is precisely what regulatory inspectors are trained to probe.

Current Good Manufacturing Practices (cGMP) vs. GMP

The terms are often used interchangeably, but there’s a meaningful distinction. GMP describes the baseline regulatory framework: the fixed set of requirements a manufacturer must meet. Current Good Manufacturing Practices (cGMP) adds an ongoing obligation that manufacturers continuously adopt current systems, equipment, and methods rather than relying on outdated approaches simply because they were once compliant.

In the United States, the FDA enforces its requirements specifically as current Good Manufacturing Practices under the Federal Food, Drug, and Cosmetic Act. This is why a facility can be technically GMP-compliant on paper while still drawing FDA criticism if its systems, software, or monitoring approach have fallen behind what “current” practice now looks like — data integrity and electronic records are the area where this gap shows up most often in 2026 inspections.

Global GMP Guidelines and Regulations

Regulatory expectations for GMP originate from several overlapping authorities, and understanding which guidelines apply to a given market is a prerequisite for compliance planning. In the United States, FDA enforcement under the Federal Food, Drug, and Cosmetic Act results in Form 483 observations, warning letters, import alerts, or facility shutdowns for non-compliance. The European Medicines Agency oversees GMP regulations across EU member states through directives covering manufacturing authorization and Qualified Person responsibilities. The World Health Organization’s GMP guidelines are used by more than 100 countries to underpin national regulatory frameworks, particularly in markets still building out independent inspection capacity.

These three regulatory bodies don’t always move in lockstep. As noted above, EMA’s 2026–2028 work plan is actively revising core GMP guidelines, including new AI-specific provisions under a proposed Annex 22 — meaning the “current” in current Good Manufacturing Practices is, in 2026, shifting faster on the technology front than it has in years.

GMP applies across virtually every drug category, but the compliance burden varies significantly by modality. Small-molecule generics and APIs follow well-established GMP pathways under guidelines like ICH Q7. Biologics, cell and gene therapies, and other advanced therapy medicinal products (ATMPs) carry materially higher complexity, since single-patient or small-batch production leaves little margin for error and often requires bespoke facility design.

Growth drivers accelerating GMP-compliant manufacturing demand include:

• Rising outsourcing of both drug substance and drug product manufacturing to specialized CDMOs
• Expansion of biologics, cell and gene therapy, and other advanced therapy pipelines requiring specialized GMP infrastructure
• Growing regulatory harmonization efforts across FDA, EMA, and WHO reducing duplicative compliance burden for global manufacturers
• Increased sponsor demand for CDMOs with proven inspection track records as outsourcing risk becomes a board-level concern

Growth inhibitors specific to GMP compliance and scale-up include:

• Persistent labor shortages and skills gaps in quality and manufacturing roles, cited as a significant headwind by Coherent Market Insights (2026)
• Intellectual property risk inherent in outsourcing proprietary manufacturing processes to third parties
• High capital costs of facility upgrades and qualification, which disproportionately burden smaller and mid-tier manufacturers
• Escalating compliance overhead for CDMOs managing multiple client programs across shared, multi-product facilities

The 10 Fundamental Principles of GMP

Modern GMP implementation follows ten core principles:

1. Create Standard Operating Procedures (SOPs) – Document all critical processes
2. Enforce SOPs and work instructions – Ensure consistent adherence
3. Document procedures and processes – Maintain comprehensive records
4. Validate the effectiveness of SOPs – Prove procedures work as intended
5. Design and use working systems – Implement effective quality systems
6. Maintain systems, facilities, and equipment – Ensure ongoing functionality
7. Develop job competence of workers – Provide training and development
8. Prevent contamination through cleanliness – Maintain hygiene standards
9. Prioritise quality and integrate into workflow – Embed quality culture
10. Conduct GMP audits regularly – Monitor compliance continuously

Global GMP Regulatory Landscape

United States: FDA cGMP Requirements

The US Food and Drug Administration enforces current Good Manufacturing Practices under the Federal Food, Drug, and Cosmetic Act. Non-compliance results in facility inspections, warning letters, product recalls, and import alerts restricting market access.

European Union: EMA GMP Guidelines

The European Medicines Agency oversees GMP implementation across EU member states through directives covering manufacturing authorisation, Qualified Person (QP) responsibilities, Good Distribution Practice (GDP) standards, and third-country manufacturing oversight.

WHO GMP Standards

The World Health Organization provides globally recognised GMP guidelines adopted by over 100 countries. These standards support developing regulatory frameworks, international harmonisation efforts, technical assistance programmes, and vaccine manufacturing protocols.

Manufacturing Considerations for Good Manufacturing Practice (GMP)

Manufacturers and sponsors evaluating GMP compliance need to look beyond certificates on a wall. Facility qualification status, data integrity maturity, technology transfer track record, and quality culture all determine whether a site will hold up under real regulatory scrutiny — particularly as FDA and EMA both signal continued intensification of inspection standards through 2026 and beyond.

Technology transfer deserves particular attention, since it’s one of the highest-risk moments in any outsourcing relationship. When a sponsor moves a process into a CDMO’s facility, equipment differences, raw material variability, and scale changes can all introduce deviations that weren’t present during original process development. A CDMO’s documented track record of successful transfers — including how they’ve handled deviations when they occurred — is often a better predictor of future performance than certifications alone.

Contamination control and process validation represent the other major technical pillars. Facilities handling multiple client products must demonstrate robust cross-contamination prevention, particularly for potent compounds or biologics sharing infrastructure with other programs. Meanwhile, FDA inspectors are increasingly expecting mature, continued process verification programs rather than one-time validation studies, according to The GMP Consultant (2026), reflecting a broader shift toward treating validation as an ongoing lifecycle activity rather than a completed milestone.

Key Criteria for Selecting a GMP-Compliant CDMO Partner

Selecting the right manufacturing partner requires evaluation across several dimensions simultaneously, since strength in one area rarely compensates for weakness in another:

• Current certifications and inspection history — verify active FDA, EMA, and relevant national authority approvals, and request the facility’s Form 483 and warning letter history directly rather than relying on self-reported summaries
• Data integrity and electronic systems maturity — given that data integrity issues drive the majority of warning letters, assess whether audit trails are not just generated but actively reviewed
• Technology transfer track record — request case studies or references demonstrating successful transfer of processes similar in complexity to your product
• Facility and equipment qualification status — confirm current IQ/OQ/PQ documentation and ask when equipment was last requalified
• Pharmaceutical quality management system maturity — a functioning CAPA process and closed-loop deviation resolution are stronger signals of quality culture than documentation that issues were simply logged
• Platform and modality fit — confirm genuine experience with your specific modality (small molecule, biologics, ATMP) rather than general facility capability
• Regulatory affairs resources — dedicated, in-house regulatory affairs capability signals better anticipation of evolving requirements than reliance on external consultants alone
• Financial and operational stability — a partner’s financial health directly affects their ability to sustain compliance investment over a multi-year program

Red Flags to Watch For

Certain warning signs should prompt deeper diligence before signing: reluctance to share full inspection or Form 483 history, vague or evasive answers about CAPA closure timelines, high or unexplained turnover within the quality unit, undisclosed subcontracting of critical manufacturing or testing steps, and defensive responses to direct questions about past regulatory findings.

5 Questions to Ask Shortlisted CDMOs

1. Can you share your facility’s full FDA Form 483 and warning letter history for the past five years?
2. What percentage of your CAPA actions close within their originally committed timeline?
3. How do you validate AI or automation tools used in GMP documentation, and what human review controls are in place?
4. What was your most recent technology transfer for a product of similar complexity to ours, and what challenges arose?
5. How is quality unit authority structured, and can the quality head halt production independent of commercial pressure?

Frequently Asked Questions (FAQ)

What is GMP in pharmaceutical manufacturing?

GMP is the regulatory framework requiring that pharmaceutical products be consistently produced and controlled according to defined quality standards, covering personnel, facilities, processes, documentation, and testing throughout the manufacturing lifecycle.

What is the difference between GMP and cGMP?

GMP refers to the baseline regulatory framework established by agencies such as the FDA, while current Good Manufacturing Practice (cGMP) emphasizes that manufacturers must continuously adopt current technologies and methods rather than relying on outdated systems. Both terms describe the same underlying regulatory expectations.

How do CDMOs achieve and maintain GMP certification?

CDMOs achieve certification through successful regulatory inspection by the relevant national authority, following demonstrated facility qualification, validated processes, and a functioning quality management system. Maintaining certification requires ongoing self-inspection, CAPA effectiveness, and passing periodic re-inspection cycles.

What happens during an FDA GMP inspection?

FDA investigators assess facility conditions, review batch records and documentation, evaluate laboratory controls and data integrity practices, and interview personnel. Findings are recorded on a Form 483, which is not a final ruling; if the company’s written response fails to adequately address major violations, FDA may escalate to a warning letter.

What are the most common GMP violations at CDMOs?

Laboratory controls and out-of-specification investigation failures remain the most frequently cited issues, alongside data integrity deficiencies such as audit trail gaps and process validation shortfalls, particularly around mature continued process verification programs, according to The GMP Consultant (2026).

How do I verify a CDMO’s GMP compliance status?

Request the facility’s current regulatory certificates directly from the CDMO, cross-reference FDA’s public warning letter database and compliance actions data dashboard, and ask for recent Form 483 responses and CAPA closure evidence rather than relying solely on the CDMO’s self-reported compliance status.

Evaluating a manufacturing partner’s GMP track record shouldn’t require chasing down scattered public records — PharmaSource’s supplier intelligence platform helps pharma and biotech teams find, compare, and vet GMP-compliant CDMO partners in one place.